Argonaut Manufacturing Services Announces the Opening of a Custom Controls & Standards facility
- S&P 500, Dow climb for third day and close at records
- Tesla (TSLA) China Numbers 'Robust' - Wedbush
- Apple (AAPL) Shares Seen as 'Attractive' as Recent Checks Show Continuously Strong Demand - Citi
- Amazon.com warehouse workers vote to reject forming union in Alabama
Get inside Wall Street with StreetInsider Premium. Claim your 1-week free trial here.
CARLSBAD, Calif., Feb. 2, 2021 /PRNewswire/ -- Argonaut Manufacturing Services ('Argonaut'), a leading contract manufacturing organization for Life Science, Diagnostic, and BioPharma markets today announced the launch of a new service offering in support of the growing need for custom controls, standards and verification panels. The service of formulating and filling these products will be performed at a newly commissioned, state-of-the-art, standalone facility located in Carlsbad, CA. This site is designed to alleviate many of the concerns expressed with the manufacturing challenges associated with positive controls and nucleic acid templates. Controls and standards are used regularly by innovators to verify instruments, reagents, and diagnostic tests to ensure SOP's are followed properly for patient samples.
The Custom Molecular Controls and Standards service provides organizations, focusing on diagnostics for the regulated markets and RUO assays, a complete solution for not only their commercial products with Argonaut but also controls that match the same high-quality standards that Argonaut Manufacturing Services provides.
"This service offering has been widely requested by our clients in every market from Point of Care device makers to platform companies," stated Wayne Woodard, CEO of Argonaut. "Providing another step in the complete solution to our clients contract manufacturing needs was our aim and when combined with our liquid or lyophilization format delivery option, we believe we have enabled a much needed compelling alternative."
The Argonaut Custom Molecular Controls and Standards provides a wide range of solutions including synthetic PCR controls, antibodies, buffers, and markers. Additionally, controls and standards can be lyophilized to both extend shelf-life and improve protocols.
"Rather than being restricted to off-the-shelf controls or putting in the capital equipment and labor-intensive SOP's to manufacture their own controls, Argonaut clients can quickly add controls that are specific for their assays," reported Eric Blair, COO of Argonaut. "With our strength in lyophilization, we think our Custom Molecular Controls and Standards service offers unparalleled opportunities for improving assays by removing saving costs, reducing waste due to shelf-life issues, and simplifying protocols by reducing pipetting and mixing steps."
To learn more about Argonaut Custom Molecular Controls and Standards, click here.
About Argonaut Manufacturing ServicesArgonaut Manufacturing Services is an FDA registered, FDB approved, ISO 13485:2016 cGMP contract manufacturing organization dedicated to providing custom manufacturing and supply chain solutions for life science, molecular diagnostics, and biopharmaceutical companies. Life sciences and molecular diagnostics services include formulation, filling, lyophilization, and kitting, while biopharmaceutical services feature state-of-the-art automated aseptic fill-finish equipment for sterile injectable drugs. All projects are supported by a senior project management group, full analytical quality control service offering and global shipping logistics. From procurement through distribution, Argonaut provides a wide range of flexible solutions for diverse outsourcing needs. www.argonautms.com
Contact: James GilmoreCompany: Argonaut Manufacturing ServicesCell Phone: (760) 277-5982Email: firstname.lastname@example.org
View original content to download multimedia:http://www.prnewswire.com/news-releases/argonaut-manufacturing-services-announces-the-opening-of-a-custom-controls--standards-facility-301219702.html
SOURCE Argonaut Manufacturing Services
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Mirati Therapeutics Presents Preclinical Data on Novel Approach to PRMT5 Inhibition that Selectively Targets the PRMT5/MTA Complex in MTAP-Deleted Cancer Models
- Fusion Pharmaceuticals Announces Preclinical Combination Data Demonstrating Enhanced Efficacy in Multiple Preclinical Tumor Models
- St. Vincent Nurses Will Begin Sixth Week on Strike for Safer Patient Care on April 11, as Dallas-Based Tenet's Cost to Avoid Negotiating a Settlement Will Surpass $33.5 million